title: Pembrolizumab for melanoma- safety profile and future trends.
authors.affiliation: a Department of Medicine (Hematology/Oncology), Melanoma Clinical Research , UCSF Helen Diller Comprehensive Cancer Center , San Francisco , CA , USA.
authors.forename: Adil
authors.initials: A
authors.lastname: Daud
authors.affiliation: a Department of Medicine (Hematology/Oncology), Melanoma Clinical Research , UCSF Helen Diller Comprehensive Cancer Center , San Francisco , CA , USA.
authors.forename: Prachi
authors.initials: P
authors.lastname: Nandoskar
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab
keywords: Melanoma; PD-1; cancer immunotherapy; pembrolizumab; safety